3649 results for «466»
3649 results
Rapid fire session on next generation structural heart and valve therapies
18 May 2026 – From EuroPCR 2026
An intensive rapid-fire session presenting the latest advancements in next-generation structural heart and valve therapies, including novel transcatheter systems for aortic and mitral valve repair, innovative solutions for tricuspid regurgitation, and implant-free PFO closure technologies.
Rapid fire session on vascular innovation, interventional technologies and hypertension
18 May 2026 – From EuroPCR 2026
This rapid fire session showcased cutting-edge innovations in vascular interventions, interventional technologies, and hypertension management. Highlights included three-dimensional OCT-guided ultrafast laser atherectomy for calcified lesions, a novel biodegradable metallic stent, intelligent pressure-controlled perfusion to prevent acute limb ischemia, a microneedle balloon catheter, personalized arterial hypertension control...
The microcirculation: the next frontier in coronary practice
18 May 2026 – From EuroPCR 2026
Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.
The Jon DeHaan Foundation Award competition
18 May 2026 – From EuroPCR 2026
Explore the forefront of interventional cardiology innovation with the Jon DeHaan Foundation Award competition, featuring pioneering solutions for valvular heart disease and mechanical support. This session highlights novel devices such as TriFlo for tricuspid regurgitation, the extravascular ventricular assist device (eVAD System), and the first-in-human experience...
RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
01 Sep 2024
Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.
The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Author
Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data
19 Sep 2022
Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.

Author
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
22 Mar 2022
Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.

Author
Transcatheter aortic valve implantation without routine percutaneous coronary intervention: A randomized controlled trial (PRO-TAVI Trial)
29 Mar 2026
Jonathan Curio provides his take on the PRO-TAVI trial presented by Michiel Voskuil at ACC.26 in New Orleans and simultaneously published in The Lancet.

Author
Aortic stenosis and coronary artery disease: which should be treated first?
18 Jun 2026
In this review, Henryk Dreger explores the complex interplay between aortic stenosis and coronary artery disease, highlighting the latest evidence on PCI timing and its implications for clinical decision-making.

Author